Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy

Lower Urinary Tract Symptoms Clinical Trial

Official title:

Clinical Investigation to Evaluate the Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04192474
• Other study ID #: CIS-014
• Status: Completed
• Phase: N/A
• Start date: July 21, 2020
• Est. completion date: June 30, 2021

Study information

• Verified date: September 2020
• Source: Ambu A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the new aScope 4 Cysto is used to see if this new single use, flexible cystoscope performs as well as other routinely used flexible cystoscopes. This study will be done in patients who come to the clinic for either a diagnosis of their urethra and bladder or for a small intervention. For an intervention a lesion or tumor is resected, a stent in the ureter is taken out, or an injection in the bladder wall is given. The flexible cystoscope is passed into the urethra and bladder for visual inspection of the bladder and urethra. It will give information on how well the structures of the urinary tract and bladder can be viewed including any abnormalities that are present. If an intervention is performed the aScope 4 Cysto will be used with an endoscopic accessory.

Description:

Clinical Phase: pre-CE study Design: A prospective, multicenter, single- arm open-label clinical study on the performance and safety of Ambu® aScope™ 4 Cysto and aView™ Urologia, a single-use, flexible cystoscope for flexible cystoscopy Population: Adult subjects (≥ 18 years) undergoing flexible cystoscopy for diagnostic or therapeutic purposes. Planned Sample Size: A total of 80 patients will result in a maximum (if the true proportion is 50 %) width (i.e. the difference between the point estimate and the upper, or lower, limit of the confidence interval) of the two-sided 95 % confidence interval for the binary variable "Performance level acceptable" to be 11%. This width is considered to be useful in the interpretations of the results from this part of the trial. Study duration: Screening, procedure and follow-up will take 14 days maximum. A follow-up telephone call at 7 days post procedure is performed to record any adverse events post-procedure. Planned Trial Period: 3 months Investigational Device: Ambu® aScope™ 4 Cysto and aView™ Urologia. A pre-CE, single use cystoscope.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 83
• Est. completion date: June 30, 2021
• Est. primary completion date: April 7, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults (males and females), =18 years of age or older, presenting for cystoscopy
• Ambulatory with a need to undergo cystoscopy for diagnostic or therapeutic purposes
• Willing to participate in a clinical trial

Exclusion Criteria:

• History of high-grade bladder cancer or carcinoma-in-situ of the bladder, undergoing cystoscopy for follow-up/surveillance purposes
• History of prior bladder/urethral reconstructive surgery
• Presence of symptomatic urinary tract infection (UTI)
• Known unpassable urethral stricture
• Unable to read and/or understand the study requirements
• Unable or unwilling to provide consent to participation in the study
• Pregnant or lactating women

Related Conditions & MeSH terms

• Bladder Disease
• Cystoscope
• Lower Urinary Tract Symptoms
• Urinary Bladder Diseases

Intervention

Device:
• Flexible cystoscopy
Treatment with the investigational device: Ambu® aScope™ 4 Cysto

Locations

Country	Name	City	State
Denmark	Herlev Hospital	Herlev
Netherlands	Erasmus MC	Rotterdam

Sponsors (2)

Lead Sponsor	Collaborator
Ambu A/S	QserveCRO

Countries where clinical trial is conducted

Denmark,  Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance of the cystoscope	Rate of completion of procedure with Ambu® aScope™ 4 Cysto and aView™ Urologia (yes/no, yes applies to 80% of the procedures)	follow up immediately after procedure
Secondary	Overall performance	The overall performance will be further assessed by using a 5-point Likert scale with a minimum of one (=worst possible) to maximum of five (=best possible), to be completed by the investigator that performed the cystoscopy	follow up immediately after procedure
Secondary	Procedure time	Procedure time in minutes	follow up immediately after procedure
Secondary	Patient Tolerance	Patient tolerance to the procedure measured by 10-points visual analogue scale (VAS) after the flexible cystoscopy. VAS from 0= minimum discomfort and 10=maximum discomfort.	follow up immediately after procedure
Secondary	Adverse events	Adverse events evaluation during and immediately after procedure	follow up immediately after procedure
Secondary	Adverse events	Adverse events from discharge up to 7 days post-procedure (follow-up call)	follow-up at 7 days after procedure